NASDAQ:GRI

GRI Bio Q2 2025 Earnings Results & Report

GRI Bio logo
$1.12 0.00 (0.00%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.18 +0.06 (+5.27%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRI Bio met analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$36.68 versus the -$36.68 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

GRI Bio EPS Results

Actual EPS
-$36.68
Consensus EPS
-$36.68
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 5 quarters

GRI Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

GRI Bio's Q4 2026 earnings is estimated for Friday, January 29, 2027, based on past reporting schedules

Earnings Documents

GRI Bio Q2 2025 Earnings FAQ

GRI Bio (NASDAQ:GRI) reported earnings of -$36.68 per share for Q2 2025, matching the consensus estimate of -$36.68. The report was announced on Thursday, August 14, 2025.

GRI Bio's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for GRI Bio on the company's earnings history page.

GRI Bio Earnings Headlines

FY2026 Earnings Estimate for GRI Bio Issued By HC Wainwright
“IMPERIUM”: The #1 investment of 2027
Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A NASA scientist says it's "bigger than AI." A Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money & Markets, calls the technology Imperium. He says it's set to spark a major investment megatrend, with one small Silicon Valley company at the center.tc pixel
See More GRI Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email.

About GRI Bio

GRI Bio (NASDAQ:GRI) is a clinical-stage biotechnology company developing therapies for inflammatory, fibrotic and autoimmune diseases. Its research focuses on invariant natural killer T (iNKT) cells, a type of immune cell involved in regulating inflammation and immune responses.

The company’s lead candidate, GRI-0621, is an oral investigational therapy being developed for idiopathic pulmonary fibrosis, a progressive lung disease. GRI Bio is also advancing other drug candidates that target iNKT-cell biology for potential use in immune-mediated conditions.

GRI Bio’s programs are in development, and its candidates have not been approved for commercial use. The company is based in the United States.

View GRI Bio Profile